LATEST addition to the range of anti-idiotypic antibodies from AbD Serotec are used to target Herceptin (Trastuzumab), an anti-cancer drug. The six new antibodies are useful for monitoring patient serum for Herceptin levels, and have potential applications in preclinical research.
The anti-Herceptin antibodies are available in three formats – high and ultra-high affinity monovalent Fab antibodies, and fully human IgG1 antibodies – to accommodate many assay requirements
“We produced six new antibodies targeting Herceptin, in response to demand, and to complement our product offering to CROs and researchers worldwide” said Victoria Warltier, market segment manager for AbD Serotec.
The company reports that it has several further anti-idiotypic antibodies in the pipeline, to be marketed this year (2012), which exploit the potential of HuCal (Human Combinatorial Antibody Library) technology for the generation of specific fully-human antibodies.